Shyam Mohan Srinivas, MD
Diagnostic Radiology · Orange
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 25 years
- University of California, Irvine, California College of Medicine, 2001
Offices
1 location · UC Regents · 105 clinicians in this group
Hospitals listed: Uci Health-Orange. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Srinivas’s office at (714) 456-7004 to ask if they take your plan before you enroll.
California Medical Board record
Licence C139917 · Current
Licensed to practise in California · since 2015 · expires 2027-09-30 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Nuclear Medicine - Nuclear Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Uci Health-OrangeOrange, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Chao Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.44 (3.82 to 7.06) · 2,934 cases, Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 82.98 (46.2 to 119.76) · 170 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.422, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.56, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.547, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.356, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.449, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 1,287 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Uci Health-Orange
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.44 (3.82 to 7.06) · 2,934 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 82.98 (46.2 to 119.76) · 170 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.422 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.56 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.547 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.356 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 1,287 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.25 to 1.87) · 2,297 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.67 to 1.13) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 59 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 104 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.3 · 331 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 416 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 330 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,269 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.33) · 8,263 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.37) · 8,703 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.95 (0.57 to 3.32) · 1,647 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.52 (1.33 to 3.71) · 2,756 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.15 (2.82 to 11.48) · 1,643 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.78 (2.24 to 7.33) · 1,680 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.61 to 3.36) · 871 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.28 (0 to 0.77) · 7,232 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 170 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.546 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 165 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 556 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 75.5 · 113 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0 · 391 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.4 · 436 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 556 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.1 to 6.6) · 846 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.8 (10 to 14) · 846 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.9 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 110 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.6 to 13.8) · 2,457 cases | No different | Jan 2022 – Dec 2024 |
What patients said (575 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$126,320
Medicare paid this office $126,320 for 616 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine study from skull base to mid-thigh with ct scan | 43 | $63,999 | $1,488 |
| Nuclear medicine study whole body with ct scan | 11 | $16,729 | $1,521 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 49 | $13,759 | $281 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 115 | $11,018 | $93 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 81 | $4,925 | $60 |
See all 14 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 43 | $63,999 | $1,488 |
| Nuclear medicine study whole body with ct scan | 11 | $16,729 | $1,521 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 49 | $13,759 | $281 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 115 | $11,018 | $93 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 81 | $4,925 | $60 |
| Nuclear medicine study whole body with ct scan | 17 | $1,695 | $89 |
| Nuclear medicine study limited area with ct scan | 18 | $1,507 | $84 |
| Dxa bone density measurement of hip, pelvis, spine | 112 | $1,097 | $10 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 13 | $721 | $55 |
| Dxa bone density measurement of hip, pelvis, spine | 69 | $676 | $10 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 16 | $662 | $41 |
| Nuclear medicine study of lymphatic system | 14 | $596 | $43 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 14 | $508 | $36 |
| Nuclear medicine study of bone and/or joint whole body | 15 | $482 | $32 |
Who their Medicare patients are
616 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 14% · Women 56% · Also on Medicaid 39% · Health risk score 2.00. Above the middle of the specialty; the typical diagnostic radiology clinician is at 1.7.
Conditions among them: High blood pressure 75% · Diabetes 38% · Cancer 33% · Coronary heart disease 32% · Chronic kidney disease 32% · Heart failure 23% · Depression 23% · Atrial fibrillation 20% · COPD 14% · Stroke 13% · Dementia 11%.
The office billed $833,963, Medicare allowed $158,764 and paid $126,320; for 706 services of 36 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 616 | 706 | 74 | 2.00 | $833,963 | $126,320 |
| 2023 | 472 | 1,094 | 72 | 2.21 | $448,679 | $106,480 |
| 2022 | 310 | 555 | 71 | 2.20 | $239,321 | $69,283 |
| 2021 | 243 | 797 | 70 | 2.04 | $130,026 | $32,003 |
| 2020 | 244 | 381 | 71 | 2.23 | $90,177 | $23,359 |
| 2019 | 32 | 52 | 68 | 2.29 | $11,914 | $3,230 |
| 2017 | 529 | 577 | 72 | 2.17 | $264,247 | $43,569 |
| 2016 | 389 | 414 | 72 | 2.06 | $196,208 | $34,653 |
| 2015 | 56 | 368 | 75 | 1.21 | $328,000 | $38,554 |
| 2014 | 791 | 1,012 | 71 | 1.86 | $1,297,212 | $192,775 |
| 2013 | 793 | 997 | 71 | 1.90 | $1,004,195 | $138,703 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 40 | $26,097 | $637 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 112 | $10,361 | $89 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 34 | $6,621 | $189 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 25 | $1,559 | $62 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 31 | $1,453 | $37 |
| Radioactive drug therapy through a vein | 16 | $1,377 | $69 |
| Nuclear medicine study of bone and/or joint whole body | 37 | $1,126 | $28 |
| Nuclear medicine study of lung ventilation and circulation | 14 | $566 | $40 |
| Nuclear medicine study of parathyroid with spect and ct scan | 12 | $534 | $45 |
| Nuclear medicine study of lymphatic system | 11 | $456 | $41 |
| Dxa bone density measurement of hip, pelvis, spine | 37 | $374 | $10 |
| Nuclear medicine study of stomach to assess emptying | 12 | $333 | $28 |
| Dxa bone density measurement of hip, pelvis, spine | 26 | $263 | $10 |
2022: 10 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 46 | $31,218 | $664 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 49 | $4,267 | $87 |
| Nuclear medicine study whole body with ct scan | 12 | $3,295 | $275 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 21 | $1,743 | $79 |
| Nuclear medicine study of bone and/or joint whole body | 42 | $1,349 | $31 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 27 | $1,202 | $38 |
| Ct scan of soft tissue of neck with contrast | 12 | $667 | $51 |
| Nuclear medicine study of parathyroid with spect and ct scan | 11 | $589 | $54 |
| Nuclear medicine study of bone and/or joint whole body | 18 | $521 | $29 |
| Nuclear medicine study of lung ventilation and circulation | 12 | $493 | $38 |
2021: 9 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 51 | $15,882 | $294 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 31 | $2,938 | $92 |
| Ct scan of abdomen and pelvis with contrast | 13 | $1,594 | $123 |
| Ct scan of chest with contrast | 14 | $797 | $57 |
| Ct scan of soft tissue of neck with contrast | 12 | $793 | $66 |
| Ct scan of soft tissue of neck with contrast | 14 | $724 | $48 |
| Nuclear medicine study of bone and/or joint whole body | 21 | $685 | $33 |
| Nuclear medicine study of bone and/or joint whole body | 18 | $554 | $31 |
| Nuclear medicine study of lung ventilation and circulation | 13 | $524 | $40 |
2020: 13 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 55 | $5,321 | $93 |
| Ct scan of abdomen and pelvis with contrast | 21 | $1,559 | $74 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 16 | $1,547 | $97 |
| Nuclear medicine study from skull base to mid-thigh | 16 | $1,208 | $76 |
| Ct scan of chest with contrast | 21 | $1,014 | $48 |
| Ct scan of soft tissue of neck with contrast | 17 | $909 | $53 |
| Nuclear medicine study from skull base to mid-thigh | 12 | $908 | $76 |
| Ct scan of abdomen and pelvis with contrast | 12 | $879 | $73 |
| Nuclear medicine study of lung ventilation and circulation | 18 | $767 | $43 |
| Ct scan of soft tissue of neck with contrast | 14 | $755 | $54 |
| Nuclear medicine study of bone and/or joint whole body | 20 | $693 | $35 |
| Nuclear medicine study of bone and/or joint whole body | 16 | $590 | $35 |
| Ct scan of chest with contrast | 12 | $579 | $48 |
2017: 8 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 191 | $20,270 | $102 |
| Nuclear medicine study whole body with ct scan | 64 | $6,873 | $104 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 32 | $3,451 | $108 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 48 | $3,258 | $68 |
| Nuclear medicine study of bone and/or joint whole body | 60 | $2,059 | $34 |
| Nuclear medicine study of lymphatic system | 21 | $1,008 | $48 |
| Nuclear medicine study of lung ventilation and circulation | 21 | $1,004 | $48 |
| Nuclear medicine study of stomach to assess emptying | 30 | $951 | $32 |
2016: 6 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 207 | $22,542 | $107 |
| Nuclear medicine study whole body with ct scan | 41 | $4,552 | $108 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | $1,848 | $71 |
| Nuclear medicine study of bone and/or joint whole body | 27 | $993 | $37 |
| Nuclear medicine study of lung ventilation and circulation | 17 | $805 | $47 |
| Nuclear medicine study of stomach to assess emptying | 17 | $559 | $33 |
2015: 4 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 56 | $19,922 | $356 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 56 | $9,890 | $88 |
| Injection, regadenoson, 0.1 mg | 36 | $5,938 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 56 | $2,803 | $50 |
2014: 19 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 73 | $62,869 | $796 |
| Nuclear medicine study of brain with metabolic evaluation | 58 | $59,064 | $557 |
| Occlusion of growths or obstructed vessels with review by radiologist | 13 | $6,162 | $440 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 48 | $4,509 | $94 |
| Nuclear medicine study of lung ventilation and circulation | 106 | $4,378 | $40 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 39 | $3,920 | $98 |
| Nuclear medicine study of bone and/or joint whole body | 111 | $3,571 | $32 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 43 | $2,648 | $62 |
| Nuclear medicine study of stomach to assess emptying | 60 | $1,797 | $30 |
| Nuclear medicine study of bone taken at different times | 37 | $1,454 | $39 |
| Nuclear medicine study of lymphatic system | 30 | $1,388 | $46 |
| Nuclear medicine study of brain | 26 | $1,103 | $42 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 22 | $766 | $35 |
| Nuclear medicine study to assess blood loss | 20 | $764 | $38 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 13 | $600 | $46 |
| Nuclear medicine study of kidney, blood flow, and function | 16 | $584 | $37 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 14 | $570 | $41 |
| Nuclear medicine study of lung ventilation and blood flow to lung | 18 | $470 | $26 |
| Nuclear medicine study of thyroid and thyroid function | 12 | $233 | $19 |
2013: 17 services
| Nuclear medicine study of brain with metabolic evaluation | 81 | $51,841 | $384 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 47 | $41,083 | $806 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 67 | $5,846 | $87 |
| Nuclear medicine study of lung ventilation and circulation | 100 | $3,997 | $40 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 63 | $3,666 | $58 |
| Nuclear medicine study of bone and/or joint whole body | 96 | $2,890 | $30 |
| Nuclear medicine study of bone and/or joint whole body | 13 | $2,236 | $172 |
| Nuclear medicine study of stomach to assess emptying | 69 | $2,004 | $29 |
| Nuclear medicine study of bone taken at different times | 36 | $1,252 | $35 |
| Nuclear medicine study of brain | 23 | $1,008 | $44 |
| Nuclear medicine study of lymphatic system | 22 | $978 | $44 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 16 | $704 | $44 |
| Nuclear medicine study of lung ventilation and blood flow to lung | 24 | $671 | $28 |
| Nuclear medicine study of kidney, blood flow, and function | 18 | $625 | $33 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 16 | $548 | $34 |
| Nuclear medicine study of thyroid and thyroid function | 18 | $316 | $18 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 14 | $272 | $18 |
Medicaid work
$5,667 in 2024
Medicaid paid $5,667 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 12 | $5,667 |
| 2024 | 12 | 1 | 12 | $5,667 |
| 2023 | 81 | 1 | 26 | $32,107 |
See the largest Medicaid services in earlier years
2023
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 81 | $32,107 |
Money from drug and device companies
$7,903 in 2025
| 2025 | 6 | 16 | $7,095 | $7,903 |
| 2024 | 4 | 10 | $1,900 | $2,403 |
| 2023 | 5 | 15 | $4,200 | $6,728 |
| 2022 | 5 | 11 | $3,920 | $4,275 |
| 2020 | 2 | 2 | $3,625 | $3,625 |
| 2019 | 2 | 2 | None | $144 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Telix Pharmaceuticals | Illuccix | $4,206 | 6 payments
|
| Ge Healthcare | Starguide | $3,411 | 5 payments
|
| Siemens Medical Solutions USA | Biograph Trinion Ep Ct64 | $89 | 1 payment
|
| Alnylam Pharmaceuticals | Amvuttra | $86 | 1 payment
|
| Blue Earth Diagnostics | Posluma | $58 | 1 payment
|
| Novartis Pharmaceuticals | Pluvicto | $53 | 2 payments
|
See all 16 published payments
| Telix Pharmaceuticals | Consulting · 2025-11-20 | Illuccix | $2,200 |
| Telix Pharmaceuticals | Consulting · 2025-11-06 | None | $1,650 |
| Telix Pharmaceuticals | Meals · 2025-09-26 | Illuccix | $133 |
| Ge Healthcare | Paid to speak or teach · 2025-07-23 | Starguide | $2,360 |
| Ge Healthcare | Paid to speak or teach · 2025-07-23 | Starguide | $885 |
| Novartis Pharmaceuticals | Meals · 2025-06-23 | Pluvicto | $26 |
| Siemens Medical Solutions USA | Meals · 2025-06-23 | Biograph Trinion Ep Ct64 | $89 |
| Ge Healthcare | Meals · 2025-06-21 | None | $105 |
| Telix Pharmaceuticals | Meals · 2025-05-01 | None | $59 |
| Telix Pharmaceuticals | Meals · 2025-04-30 | None | $42 |
| Blue Earth Diagnostics | Meals · 2025-03-28 | Posluma | $58 |
| Alnylam Pharmaceuticals | Meals · 2025-02-01 | Amvuttra | $86 |
| Ge Healthcare | Meals · 2025-01-31 | None | $27 |
| Telix Pharmaceuticals | Meals · 2025-01-30 | Illuccix | $122 |
| Novartis Pharmaceuticals | Meals · 2025-01-30 | Pluvicto | $26 |
| Ge Healthcare | Meals · 2025-01-08 | None | $34 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $2,403
| Blue Earth Diagnostics | Posluma | $2,104 | 4 payments
|
| Telix Pharmaceuticals | Illuccix | $215 | 4 payments
|
| Ge Healthcare | None | $54 | 1 payment
|
| Novartis Pharmaceuticals | Pluvicto | $29 | 1 payment
|
2023: $6,728
| Progenics Pharmaceuticals | Pylarify | $4,359 | 7 payments
|
| Telix Pharmaceuticals | Illuccix | $2,241 | 5 payments
|
| Novartis Pharmaceuticals | Lutathera | $83 | 1 payment
|
| Ge Healthcare | None | $22 | 1 payment
|
| Blue Earth Diagnostics | Posluma | $22 | 1 payment
|
2022: $4,275
| Progenics Pharmaceuticals | Pylarify | $4,101 | 6 payments
|
| Novartis Pharmaceuticals | Lutathera | $80 | 2 payments
|
| Sirtex Medical | Sir-Spheres Microspheres | $60 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $19 | 1 payment
|
| GE HealthCare | None | $15 | 1 payment
|
2020: $3,625
| Advanced Accelerator Applications | None | $3,125 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $500 | 1 payment
|
2019: $144
| UIH Solutions | None | $82 | 1 payment
|
| Varian Medical Systems | None | $62 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Aveo Pharmaceuticals, Inc. · Tinivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib in Combination With Nivolumab To Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines of Therapy Where One Line Has An Immune Checkpoint Inhibitor · 2025 | Their institution | $7,095 |
| Telix Pharmaceuticals · R591-Tx: 177lu-Tlx591-203: Prostact Global: Trial · 2024 | Their institution | $3,000 |
| Siemens Medical Solutions USA, Inc. · Software License UC Irvine Proframer Tool · 2025 | Their institution | $29 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 79.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1194739425
- Licence
- CA C139917California C139917: Current · expires 2027-09-30
- Trained
- University of California, Irvine, California College of Medicine, 2001 · 25 years ago
- Group
- UC Regents
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2085N0904X (2085N0904X)
- Mailing address
- 300 Pasteur Dr, Suite 200, Stanford, CA, 94305
- NPI first listed
- 2006-07-29
- NPI last updated
- 2021-06-15
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.